Over the course of the last 15 years, bioelectronic medicine at the Feinstein Institute has evolved from an accidental lab discovery to a nationally recognized leader in the emerging field, and we couldn’t do it without our partners and collaborators that make it all possible.
The Feinstein Institute is fortunate to partner with leading academic institutions, non-profits, technologists, and pharmaceutical companies, but as the field expands beyond the microscope and into device commercialization, so too must our partners expand and grow with us.
If you’re interested in learning more about strategic partnership opportunities, please email us.
Cold Spring Harbor Laboratory: Cold Spring Harbor Laboratory (CSHL) is a private, non-profit institution with research programs focusing on cancer, neuroscience, plant genetics, genomics and quantitative biology. It is one of 68 institutions supported by the Cancer Centers Program of the U.S. National Cancer Institute (NCI) and has been an NCI-designated Cancer Center since 1987. CSHL is ranked among the leading basic research institutions in the world in molecular biology and genetics and is one of a handful of institutions that played a central role in the development of molecular genetics and molecular biology.
Karolinska Instituet: Based in Stockholm, Sweden, Karolinska is one of the largest and most prestigious medical universities in the world. It consistently ranks among the top universities in the world. Research at Karolinska Instituet accounts for more than 40% of all academic medical research in Sweden. It is also the home of the Nobel Prize. Dr. Peder Olofsson, who worked at the Feinstein between 2009 and 2015, has recently returned to Karolinska as Founding Director of their Center for Bioelectronic Medicine. The Feinstein applauds Karolinska’s commitment to this new field, and is providing organizational and strategic support as necessary.
SetPoint Medical: SetPoint Medical is dedicated to treating patients with debilitating inflammatory diseases, such as Crohn’s disease and rheumatoid arthritis, using proprietary implantable neuromodulation devices. The Scientific platform is based on the Inflammatory Reflex – the natural mechanism by which the central nervous system regulates the immune system. This mechanism was discovered by SetPoint co-founder Dr. Kevin J. Tracey and published in Nature in May 2000. Since then, the Inflammatory Reflex has been characterized in more than 100 peer-reviewed papers in leading scientific journals. Anti-inflammatory potency comparable to leading drugs has been demonstrated in multiple animal models. The company is currently conducting human trials in rheumatoid arthritis at four European centers. SetPoint’s microregulator is designed to supplement the body’s natural Inflammatory Reflex by providing ‘built-in’ therapy at a lower cost and is intended to improve safety compared with drugs or biologic solutions.
Battelle: Battelle is an international science and technology enterprise that explores emerging areas of science, develops and commercializes technology, and manages laboratories for the federal government and other customers. Battelle applies science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Battelle is the world’s largest nonprofit research and development organization, with over 22,000 employees at more than 60 locations globally. A 501(c)(3) charitable trust, Battelle was founded on industrialist Gordon Battelle’s vision that business and scientific interests can go hand-in-hand as forces for positive change.